Compare GSK plc (GSK) vs T-Rex 2X Inverse MSTR Daily Target ETF (MSTZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs T-Rex 2X Inverse MSTR Daily Target ETF — how do they compare? GSK plc trades at $46.52 (market cap $91.88B), while T-Rex 2X Inverse MSTR Daily Target ETF trades at $2.61 (market cap $94.46M). The key difference: GSK plc is far larger — about 972.7× T-Rex 2X Inverse MSTR Daily Target ETF's market cap, and GSK plc pays a 3.9% dividend while T-Rex 2X Inverse MSTR Daily Target ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold GSK plc for 93 Days and T-Rex 2X Inverse MSTR Daily Target ETF for 8 Days on average.
| GSK | MSTZ | |
|---|---|---|
Market Cap | $91.88B | $94.46M |
Volume | 7,730,529 | 104,717,733 |
Sector | Health | Leveraged / Inverse |
52-Week High | $61.18 | $27.92 |
52-Week Low | $43.24 | $2.29 |
Typical Hold Time | 93 Days | 8 Days |
Enterprise Value | $111.88B | — |
Dividend Yield | 3.9% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $46.50, down 1.11% with bearish technical signals, though RSI levels suggest potential oversold conditions. Fundamentally, the company shows strong profitability with 72.73% gross margins and consistent earnings beats, while maintaining a reasonable P/E of 14.89. Recent developments include strategic oncology partnerships and a $750M cancer therapy acquisition, positioning for long-term growth despite facing an HIV patent cliff.
GSK presents a mixed investment case with strong fundamentals and pipeline growth offset by technical weakness and patent expiration risks. The company's £40B sales target and cost-saving initiatives provide upside potential, while analyst consensus leans cautious with 55% hold ratings. Key risks include execution of pipeline development and competitive pressures in core markets.
MSTZ trades at $2.62, down 1.5% today, with technical indicators showing a bearish bias as moving averages signal selling pressure while oscillators remain neutral. The stock faces resistance at $3 with support at $2, indicating a tight trading range. Recent ETF coverage highlights its inclusion in leveraged fund discussions, though specific company fundamentals remain undisclosed in available data.
The outlook for MSTZ hinges on upcoming financial disclosures to clarify valuation metrics like P/E and profitability. Key risks include limited public financial data and market volatility. Investors await earnings reports to assess growth potential amid current technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About T-Rex 2X Inverse MSTR Daily Target ETF
MSTZ is a leveraged ETF that seeks daily investment results corresponding to 200% of the inverse (opposite) of the daily performance of the MicroStrategy Incorporated (MSTR) stock. It is designed as a tactical tool for experienced traders to take a bearish position on MSTR, a company known for its large Bitcoin holdings. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment, as its performance over longer periods may significantly deviate from its stated daily objective.
Read more on MSTZ →
